Sell-rated reports Includes Sell, Strong Sell, and Avoid-rated reports — all stocks our analysis flags as best avoided.

248 tickers rated Sell
Ranks this page's recent reports by score.
Cleveland-Cliffs Inc.
CLF·Materials
C ★★Sell
Current$14.03
Oct 22, 2026

Cleveland-Cliffs offers significant upside leverage to recovering U.S. steel prices and contract margins, but elevated debt, historically weak free cash flow, and cyclical operating risk undermine the durability of its investment case.

Score
57
Albertsons Companies, Inc.
ACI·Consumer Staples
C ★★Sell
Current$13.36
Oct 22, 2026

Albertsons offers a recognizable grocery franchise, meaningful dividends, and potential restructuring upside, but declining margins, weak comparable-store sales, and heavy financial obligations threaten sustainable shareholder returns.

Score
60
AGNC Investment Corp.
AGNC·Real Estate
F Avoid
Current$8.78
Oct 22, 2026

AGNC offers substantial monthly dividend income and potential upside from tighter mortgage spreads, but leveraged book-value losses, narrow payout coverage, and a premium to tangible equity undermine its current risk-reward profile.

Score
42
ManpowerGroup Inc.
MAN·Industrials
C ★★Sell
Current$41.22
Oct 20, 2026

ManpowerGroup offers cyclical recovery potential through its established global staffing franchise and discounted valuation, but weak free cash flow and uncertain profitability normalization undermine the investment case.

Score
55
Korea Electric Power Corporation
KEP·Utilities
C ★★Sell
Current$10.65
Oct 20, 2026

Korea Electric Power offers a potentially attractive earnings-recovery opportunity through its dominant electricity infrastructure, but heavy debt, regulated tariffs, and volatile fuel costs threaten sustainable cash generation.

Score
58
Atlanta Braves Holdings, Inc.
BATRK·Communication Services
D ★Strong Sell
Current$49.28
Oct 20, 2026

Atlanta Braves owns a scarce MLB franchise and valuable surrounding real estate with long-term appreciation potential, but weak cash generation, broadcasting execution risk, and concentrated voting control undermine the current investment case.

Score
53
AnaptysBio, Inc.
ANAB·Healthcare
C ★★Sell
Current$49.24
Oct 20, 2026

AnaptysBio offers exposure to growing Jemperli royalties and potentially valuable regulatory catalysts, but substantial contractual uncertainty, weak cash conversion and shareholder dilution undermine the near-term investment case.

Score
57
J.B. Hunt Transport Services, Inc.
JBHT·Industrials
C ★★Sell
Current$228.78
Oct 19, 2026

J.B. Hunt's leading intermodal network and disciplined capital returns position it for a freight-cycle recovery, but elevated valuation and persistent labor, insurance, and equipment costs threaten sustainable earnings growth.

Score
61
Aehr Test Systems, Inc.
AEHR·Technology
F Avoid
Current$69.21
Oct 16, 2026

Aehr could benefit from rapid AI processor and silicon photonics burn-in adoption, but its high valuation, concentrated customer programs, and unproven earnings recovery create substantial downside risk.

Score
46
BlackRock, Inc.
BLK·Financials
C ★★Sell
Current$1,120.78
Oct 16, 2026

BlackRock's dominant ETF franchise, accelerating organic fee growth, and private-market expansion support long-term earnings growth, but expensive cash-flow valuation and acquisition-related dilution limit near-term investment appeal.

Score
68
Neogen Corporation
NEOG·Healthcare
D ★Strong Sell
Current$12.00
Oct 13, 2026

Neogen's established food safety franchise offers meaningful turnaround potential through manufacturing efficiencies and stronger recurring consumable sales, but high leverage and demanding cash-flow valuation leave little room for execution setbacks.

Score
50